Lord's Mark Industries Limited corrected a significant pricing error in its July 23, 2026, board meeting outcome, revising the equity share issue price from ₹10 to ₹195 per share. The Mumbai-based manufacturer of medical and surgical equipment issued the corrigendum on July 24, 2026, to the Bombay Stock Exchange (BSE) after identifying an inadvertent typographical mistake in the initial disclosure. This correction ensures that investors and stakeholders have accurate information regarding the valuation and capital structure implications of the company's recent corporate action. The revised price reflects a substantial difference in consideration, impacting the total capital raised and the premium component attributed to shareholders.

The Board of Directors had originally communicated an issue price of ₹10/- per Equity Share in the outcome filed on July 23, 2026. Lord's Mark Industries Limited clarified that this figure was incorrect due to a clerical error. The accurate issue price is ₹195/- per Equity Share. This correction aligns the public record with the actual terms approved by the management for the equity issuance. The company emphasized that apart from this specific numerical correction, all other contents of the original disclosure remain unchanged and valid.

Pricing Structure Breakdown

The corrected issue price consists of two distinct components: the face value of the share and the securities premium. The breakdown of the ₹195/- per share consideration is detailed below:

This structure indicates that the majority of the issue price is attributed to the securities premium, which is credited to the Securities Premium Reserve account. This reserve can be utilized for specific purposes such as issuing bonus shares or writing off preliminary expenses, as permitted under the Companies Act. The face value remains at ₹10/-, which determines the voting rights and dividend entitlements on a per-share basis.

Regulatory Compliance and Disclosure

Lord's Mark Industries Limited submitted the corrigendum to the Manager – Listing Department at BSE Limited, located at Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai. The submission was signed by Sachidanand Hariram Upadhyay, Managing Director, with DIN 01631728. The company’s registered office is located at B-101 Riddhi Siddhi Complex, M.G. Road, Borivali (E), Mumbai, while its corporate office operates from Wagle Estate, Thane West, Maharashtra. The prompt issuance of the corrigendum demonstrates adherence to regulatory norms requiring timely and accurate disclosure of material information to stock exchanges. Investors are advised to rely on the corrected figures for any financial analysis or investment decisions related to this equity issuance.

Lords Mark Industries Limited has submitted an application to the National Stock Exchange of India Limited (NSE) seeking listing and trading approval for its existing issued, subscribed, and fully paid-up equity shares. The disclosure, made on July 24, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, signals the company’s intent to expand its market presence beyond its current listing on BSE Limited. This dual-listing strategy aims to provide a nationwide trading platform, thereby enhancing liquidity and improving accessibility for a broader investor base.

The application is part of a strategic effort to increase the visibility of the company’s equity shares, which are identified by scrip code 501261 on the Bombay Stock Exchange. By securing a listing on the NSE, Lords Mark Industries intends to tap into a larger pool of investors and improve the tradability of its shares. The move is particularly relevant for a company operating in the specialized medical device sector, where broader market access can facilitate better price discovery and capital efficiency.

Regulatory Framework and Approvals

The submission was made pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has notified the Manager – Listing Department at BSE Limited regarding this development. The proposed listing on the NSE remains subject to the receipt of necessary approvals, permissions, and observations from the National Stock Exchange of India Limited and other applicable regulatory authorities. Lords Mark Industries has committed to keeping the stock exchanges informed of any further material developments, including the final receipt of listing and trading approval.

Corporate Profile and Brand Portfolio

Lords Mark Industries Limited, formerly known as Lords Mark Industries Limited and Kratos Energy & Infrastructure Limited, operates through distinct brand verticals including LordsMed, Lord's Renal, and Lord's Surgical. These brands reflect the company’s focus on medical devices and healthcare solutions. The corporate office is located in Thane West, Maharashtra, while the registered office is situated in Borivali (E), Mumbai. The disclosure was signed by Mr. Sachidanand Hariram Upadhyay, Managing Director, who holds DIN No. 01631728.

What the Numbers Show

While this filing does not disclose specific financial metrics such as revenue or profit figures, the strategic decision to pursue a dual listing highlights management’s confidence in the company’s operational stability and growth trajectory. The absence of financial data in this specific regulatory intimation means that investors should refer to previous quarterly results or annual reports for performance indicators. However, the procedural step of applying for NSE listing often precedes increased institutional interest, as many large-cap funds prefer trading on the NSE due to its higher liquidity and electronic trading infrastructure. For shareholders, this development represents a potential improvement in share liquidity and ease of trade execution.

The company will continue to update stakeholders on the progress of the application. Until formal approval is granted by the NSE, the shares will continue to trade exclusively on the BSE. Investors are advised to monitor official communications from the company for updates on the listing timeline and any associated costs or requirements for demat account holders.